BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mancini GJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology 2016;32:S35-65. [DOI: 10.1016/j.cjca.2016.01.003] [Cited by in Crossref: 125] [Cited by in F6Publishing: 111] [Article Influence: 20.8] [Reference Citation Analysis]
Number Citing Articles
1 Fitchett D, Mancini GB, Langer A. Optimizing the Prevention of Cardiovascular Events. Can J Cardiol 2016;32:S13-4. [PMID: 27342695 DOI: 10.1016/j.cjca.2016.02.063] [Reference Citation Analysis]
2 Pedro-Botet J, Climent E, Benaiges D. Muscle and statins: from toxicity to the nocebo effect. Expert Opin Drug Saf 2019;18:573-9. [PMID: 31070941 DOI: 10.1080/14740338.2019.1615053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
3 Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology 2017;70:1290-301. [DOI: 10.1016/j.jacc.2017.07.752] [Cited by in Crossref: 121] [Cited by in F6Publishing: 103] [Article Influence: 24.2] [Reference Citation Analysis]
4 Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol 2017;11:70-79.e1. [PMID: 28391913 DOI: 10.1016/j.jacl.2016.10.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
5 Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs 2018;18:157-73. [PMID: 29318532 DOI: 10.1007/s40256-017-0259-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 17.0] [Reference Citation Analysis]
6 Casula M, Gazzotti M, Bonaiti F, OImastroni E, Arca M, Averna M, Zambon A, Catapano AL; PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med 2021;290:116-28. [PMID: 33259671 DOI: 10.1111/joim.13219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 2020;16:809-22. [PMID: 32729746 DOI: 10.1080/17425255.2020.1801634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kristiansen O, Vethe NT, Peersen K, Fagerland MW, Sverre E, Jensen EP, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects: a randomized, double blinded crossover trial. Eur Heart J Cardiovasc Pharmacother 2020:pvaa076. [PMID: 32609361 DOI: 10.1093/ehjcvp/pvaa076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Camerino GM, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S. Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence. Int J Mol Sci 2021;22:2070. [PMID: 33669797 DOI: 10.3390/ijms22042070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Robinson JG. New insights into managing symptoms during statin therapy. Progress in Cardiovascular Diseases 2019;62:390-4. [DOI: 10.1016/j.pcad.2019.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Grundy SM, Vega GL. Statin Intolerance and Noncompliance: An Empiric Approach. Am J Med 2021:S0002-9343(21)00644-6. [PMID: 34717898 DOI: 10.1016/j.amjmed.2021.09.014] [Reference Citation Analysis]
12 Haxhi J, Thompson PD. Rationale for the use of metformin and exercise to counteract statin-associated side effects. Int J Clin Pract 2021;75:e13900. [PMID: 33277775 DOI: 10.1111/ijcp.13900] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Gallo A, Perregaux J, Bruckert E. Advances in the management of statin myopathy. Curr Opin Endocrinol Diabetes Obes 2021;28:142-51. [PMID: 33278129 DOI: 10.1097/MED.0000000000000595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lee W, Kim J. Statin-induced liver and muscle toxicities. Mol Cell Toxicol 2019;15:9-17. [DOI: 10.1007/s13273-019-0002-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kajinami K, Tsukamoto K, Koba S, Inoue I, Yamakawa M, Suzuki S, Hamano T, Saito H, Saito Y, Masuda S, Nakayama T, Okamura T, Yamashita S, Kagawa T, Kaneyama J, Kuriyama A, Tanaka R, Hirata A; Statin Intolerance Clinical Guide Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics. Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb 2020;27:375-96. [PMID: 31588101 DOI: 10.5551/jat.50948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Rizos CV, Elisaf MS. Statin myopathy: navigating the maze. Curr Med Res Opin 2017;33:327-9. [PMID: 27805428 DOI: 10.1080/03007995.2016.1255601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Bellosta S, Corsini A, Ferri N. Risk Factors for SAMS. In: Thompson PD, Taylor BA, editors. Statin-Associated Muscle Symptoms. Cham: Springer International Publishing; 2020. pp. 51-61. [DOI: 10.1007/978-3-030-33304-1_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zupanic E, Kramberger MG, von Euler M, Norrving B, Winblad B, Secnik J, Fastbom J, Eriksdotter M, Garcia-Ptacek S. Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders. J Alzheimers Dis 2020;73:1013-21. [PMID: 31884483 DOI: 10.3233/JAD-191011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Petrkova J, Taborsky M, Petrek M. Pharmacogenetics of Cardiovascular Disease: Genetic Variation and Statin Intolerance. In: Liu Y, editor. Genetic Diversity and Disease Susceptibility. InTech; 2018. [DOI: 10.5772/intechopen.79518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Greco S, D'Amuri A, Giorgini E, Luciani F, Lopreiato M, Fortunato V, Scopa A, Vestita G, Capatti E, Passaro A. Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy. High Blood Press Cardiovasc Prev 2021;28:355-64. [PMID: 33905094 DOI: 10.1007/s40292-021-00452-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hodgkins AJ, Mullan J, Mayne D, Bonney A. The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients. Pharmacy (Basel) 2019;7:E134. [PMID: 31540408 DOI: 10.3390/pharmacy7030134] [Reference Citation Analysis]
22 Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol 2020;5:1124-35. [PMID: 32609313 DOI: 10.1001/jamacardio.2020.2314] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
23 Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Statin-associated muscle symptoms—Managing the highly intolerant. Journal of Clinical Lipidology 2017;11:24-33. [DOI: 10.1016/j.jacl.2017.01.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
24 Gonzalez A, Iles TL, Iaizzo PA, Bandschapp O. Impact of statin intake on malignant hyperthermia: an in vitro and in vivo swine study. BMC Anesthesiol 2020;20:270. [PMID: 33096987 DOI: 10.1186/s12871-020-01186-5] [Reference Citation Analysis]
25 Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but…. Adv Nutr 2018;9:519S-23S. [PMID: 30032220 DOI: 10.1093/advances/nmy010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Kanagalingam T, Lazarte J, Wong DKH, Hegele RA. Liver Injury Associated With Ezetimibe Monotherapy. CJC Open 2021;3:195-7. [PMID: 33644733 DOI: 10.1016/j.cjco.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res 2018;114:1073-81. [PMID: 29878063 DOI: 10.1093/cvr/cvy119] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
28 Tong AJ, Hu RK, Wu LX, Lv XC, Li X, Zhao LN, Liu B. Ganoderma polysaccharide and chitosan synergistically ameliorate lipid metabolic disorders and modulate gut microbiota composition in high fat diet-fed golden hamsters. J Food Biochem 2020;44:e13109. [PMID: 31793675 DOI: 10.1111/jfbc.13109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
29 Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. Journal of Clinical Lipidology 2018;12:78-88. [DOI: 10.1016/j.jacl.2017.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
30 Anderson TJ. Optimal Low-Density Lipoprotein Cholesterol for Cardiovascular Prevention: How Low Should We Go? Canadian Journal of Cardiology 2017;33:405-8. [DOI: 10.1016/j.cjca.2016.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Shi J, Li R, Liu Y, Lu H, Yu L, Zhang F. Shuangyu Tiaozhi Granule Attenuates Hypercholesterolemia through the Reduction of Cholesterol Synthesis in Rat Fed a High Cholesterol Diet. Biomed Res Int 2019;2019:4805926. [PMID: 30937311 DOI: 10.1155/2019/4805926] [Reference Citation Analysis]
32 Snejdrlova M, Altschmiedova T, Vrablik M, Stulc T, Lastuvka J, Lanska V, Ceska R. Statin Intolerance in Clinical Practice. Curr Atheroscler Rep 2020;22:27. [PMID: 32495058 DOI: 10.1007/s11883-020-00845-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Kariyanna PT, Haseeb S, Chowdhury YS, Jayarangaiah A, Maryniak A, Mo G, Hegde S, Marmur JD, McFarlane IM. Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review. Am J Med Case Rep 2019;7:337-41. [PMID: 31745500 DOI: 10.12691/ajmcr-7-12-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
34 Faubion SS, Kapoor E, Moyer AM, Hodis HN, Miller VM. Statin therapy: does sex matter? Menopause 2019;26:1425-35. [PMID: 31513091 DOI: 10.1097/GME.0000000000001412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
35 Page MM, Watts GF. PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes Obes Metab 2017;20:270-82. [DOI: 10.1111/dom.13070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
36 Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020;72:1479-508. [PMID: 32889701 DOI: 10.1007/s43440-020-00155-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 43.5] [Reference Citation Analysis]
37 Katsiki N, Mikhailidis DP, Bajraktari G, Miserez AR, Cicero AFG, Bruckert E, Serban MC, Mirrakhimov E, Alnouri F, Reiner Ž, Paragh G, Sahebkar A, Banach M; International Lipid Expert Panel (ILEP). Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). Pharmacol Res 2020;155:104719. [PMID: 32087236 DOI: 10.1016/j.phrs.2020.104719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Feldman RD, Fitchett D, Hegele RA, Poulter NR. Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. Canadian Journal of Cardiology 2018;34:532-5. [DOI: 10.1016/j.cjca.2018.01.091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP). The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol 2018;72:96-118. [PMID: 29957236 DOI: 10.1016/j.jacc.2018.04.040] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 41.3] [Reference Citation Analysis]
40 Mada SB, Ugwu CP, Abarshi MM. Health Promoting Effects of Food-Derived Bioactive Peptides: A Review. Int J Pept Res Ther 2020;26:831-48. [DOI: 10.1007/s10989-019-09890-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
41 Mitchell D, Guertin JR, Dubois A, Dubé MP, Tardif JC, Iliza AC, Fanton-Aita F, Matteau A, LeLorier J. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Mol Diagn Ther 2018;22:241-54. [PMID: 29651791 DOI: 10.1007/s40291-018-0323-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
42 Gaudet D, Drouin-chartier J, Couture P. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. Canadian Journal of Cardiology 2017;33:872-82. [DOI: 10.1016/j.cjca.2016.12.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
43 Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. Physiol Rev 2020;100:633-72. [PMID: 31751166 DOI: 10.1152/physrev.00002.2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
44 Suárez-Rivero JM, Pastor-Maldonado CJ, de la Mata M, Villanueva-Paz M, Povea-Cabello S, Álvarez-Córdoba M, Villalón-García I, Suárez-Carrillo A, Talaverón-Rey M, Munuera M, Sánchez-Alcázar JA. Atherosclerosis and Coenzyme Q10. Int J Mol Sci 2019;20:E5195. [PMID: 31635164 DOI: 10.3390/ijms20205195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
45 Wu S, Yang R, Wang G. Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model. Sci Rep 2017;7:6084. [PMID: 28729731 DOI: 10.1038/s41598-017-06476-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
46 Dagenais R, Leung M, Poinen K, Landsberg D. Common Questions and Misconceptions in the Management of Renal Transplant Patients: A Guide for Health Care Providers in the Posttransplant Setting. Ann Pharmacother 2019;53:419-29. [PMID: 30345802 DOI: 10.1177/1060028018809318] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol 2017;69:1386-95. [PMID: 28302290 DOI: 10.1016/j.jacc.2016.12.036] [Cited by in Crossref: 160] [Cited by in F6Publishing: 140] [Article Influence: 32.0] [Reference Citation Analysis]
48 Mancini GJ, Hegele RA, Leiter LA. Dyslipidemia. Canadian Journal of Diabetes 2018;42:S178-85. [DOI: 10.1016/j.jcjd.2017.10.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
49 Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, Michos ED, Minissian M, Pepine C, Vaccarino V, Volgman AS; ACC CVD Womens Committee Members. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2602-18. [PMID: 32439010 DOI: 10.1016/j.jacc.2020.03.060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
50 Peersen K, Munkhaugen J, Sverre E, Kristiansen O, Fagerland M, Vethe NT, Perk J, Husebye E, Dammen T. Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovasc Disord 2021;21:596. [PMID: 34915854 DOI: 10.1186/s12872-021-02422-7] [Reference Citation Analysis]
51 Penson PE, Banach M. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. Nutrients 2021;13:2957. [PMID: 34578834 DOI: 10.3390/nu13092957] [Reference Citation Analysis]
52 Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E. Statin-associated muscle symptoms in coronary patients: design of a randomized study. Scandinavian Cardiovascular Journal 2019;53:162-8. [DOI: 10.1080/14017431.2019.1612085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Tomlinson B, Chan P, Zhang Y, Liu Z, Lam CWK. Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol 2020;16:371-85. [PMID: 32223657 DOI: 10.1080/17425255.2020.1749261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Ross S, Gerstein H, Paré G. The Genetic Link Between Diabetes and Atherosclerosis. Can J Cardiol 2018;34:565-74. [PMID: 29731020 DOI: 10.1016/j.cjca.2018.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Susekov AV, Korol LA, Watts GF. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovasc Drugs Ther 2021;35:841-52. [PMID: 33502687 DOI: 10.1007/s10557-020-07139-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Bai Z, Xu M, Mei Y, Hu T, Zhang P, Chen M, Lv W, Lu C, Tan S. Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines 2021;9:1783. [PMID: 34944600 DOI: 10.3390/biomedicines9121783] [Reference Citation Analysis]
57 Du H, Li C, Wang Z, He Y, Wang Y, Zhou H, Wan H, Yang J. Effects of Danhong injection on dyslipidemia and cholesterol metabolism in high-fat diets fed rats. J Ethnopharmacol 2021;274:114058. [PMID: 33766756 DOI: 10.1016/j.jep.2021.114058] [Reference Citation Analysis]
58 Elnaem MH, Nik Mohamed MH, Zaman Huri H, Azarisman SM. Impact of educational outreach intervention on enhancing health care providers' knowledge about statin therapy prescribing in Malaysian patients with type 2 diabetes mellitus. J Eval Clin Pract 2018;24:521-7. [DOI: 10.1111/jep.12903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
59 Greabu M, Badoiu SC, Stanescu-Spinu II, Miricescu D, Totan AR, Badoiu SE, Costagliola M, Jinga V. Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review. Int J Mol Sci 2021;22:9782. [PMID: 34575946 DOI: 10.3390/ijms22189782] [Reference Citation Analysis]
60 Al-Mohaissen MA, Ignaszewski MJ, Frohlich J, Ignaszewski AP. Statin-Associated Muscle Adverse Events: Update for clinicians. Sultan Qaboos Univ Med J 2016;16:e406-15. [PMID: 28003885 DOI: 10.18295/squmj.2016.16.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
61 VanWagner LB. Asprin and statin use for management of atherosclerotic cardiovascular disease in liver transplant candidates: Are we missing the mark? Liver Transpl 2018;24:865-7. [PMID: 29781097 DOI: 10.1002/lt.25203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Berent T, Berent R, Steiner S, Sinzinger H. Statin-induced muscular side effects at rest and exercise - An anatomical mapping. Atheroscler Suppl 2019;40:73-8. [PMID: 31447216 DOI: 10.1016/j.atherosclerosissup.2019.08.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
63 Pearlman M, Covin Y, Schmidt R, Mortensen EM, Mansi IA. Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study. J Clin Pharmacol 2017;57:1053-63. [PMID: 28398604 DOI: 10.1002/jcph.895] [Reference Citation Analysis]
64 Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018;39:2526-39. [PMID: 29718253 DOI: 10.1093/eurheartj/ehy182] [Cited by in Crossref: 137] [Cited by in F6Publishing: 97] [Article Influence: 45.7] [Reference Citation Analysis]
65 Penson PE, Banach M. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. Curr Atheroscler Rep 2020;22:67. [PMID: 32945980 DOI: 10.1007/s11883-020-00887-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Alkindi M, Siminovitch KA, Gupta M, Genest J. Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. Canadian Journal of Cardiology 2016;32:1552-60. [DOI: 10.1016/j.cjca.2016.04.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
67 Takenouchi A, Tsuboi A, Kitaoka K, Minato S, Kurata M, Fukuo K, Kazumi T. Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is an Independent Determinant of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes. J Clin Med Res 2017;9:310-6. [PMID: 28270891 DOI: 10.14740/jocmr2871w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
68 Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc 2019;8:e011662. [PMID: 30922146 DOI: 10.1161/JAHA.118.011662] [Cited by in Crossref: 105] [Cited by in F6Publishing: 33] [Article Influence: 52.5] [Reference Citation Analysis]
69 Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf 2018;17:25-37. [PMID: 29058944 DOI: 10.1080/14740338.2018.1394455] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
70 Muntean DM, Thompson PD, Catapano AL, Stasiolek M, Fabis J, Muntner P, Serban MC, Banach M. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 2017;22:85-96. [PMID: 27634340 DOI: 10.1016/j.drudis.2016.09.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
71 Kuerman M, Bao Y, Guo M, Jiang S. Safety assessment of two strains and anti-obese effects on mice fed a high-cholesterol diet. Biochem Biophys Res Commun 2021;572:131-7. [PMID: 34364292 DOI: 10.1016/j.bbrc.2021.07.089] [Reference Citation Analysis]
72 Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Current Opinion in Lipidology 2019;30:1-9. [DOI: 10.1097/mol.0000000000000565] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 8.3] [Reference Citation Analysis]
73 Zhang H, Plutzky J, Ge W, Shubina M, Turchin A. Predictors of a successful statin reattempt after an adverse reaction. Journal of Clinical Lipidology 2018;12:643-51. [DOI: 10.1016/j.jacl.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
74 Teramoto T, Kondo A, Kiyosue A, Harada-Shiba M, Ishigaki Y, Tobita K, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis 2017;16:121. [PMID: 28623954 DOI: 10.1186/s12944-017-0513-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
75 Valanti EK, Dalakoura-Karagkouni K, Sanoudou D. Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis. J Pers Med 2018;8:E34. [PMID: 30282955 DOI: 10.3390/jpm8040034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
76 Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38-81. [PMID: 30580575 DOI: 10.1161/ATV.0000000000000073] [Cited by in Crossref: 170] [Cited by in F6Publishing: 74] [Article Influence: 56.7] [Reference Citation Analysis]
77 Antoniol MN, Moreno PJ, Milisenda JC, Selva O'Callaghan A, Grau JM, Padrosa J. Statin use and myopathy. Not always guilty. Rheumatology (Oxford) 2020;59:3853-7. [PMID: 32500148 DOI: 10.1093/rheumatology/keaa180] [Reference Citation Analysis]
78 Laufs U, Filipiak KJ, Gouni-Berthold I, Catapano AL; SAMS expert working group. Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler Suppl 2017;26:45-55. [PMID: 28434484 DOI: 10.1016/S1567-5688(17)30024-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
79 Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GJ, Mcpherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology 2016;32:1263-82. [DOI: 10.1016/j.cjca.2016.07.510] [Cited by in Crossref: 476] [Cited by in F6Publishing: 415] [Article Influence: 79.3] [Reference Citation Analysis]
80 Tanner RM, Colantonio LD, Kilgore ML, Mefford MT, Chachappan DT, Mues KE, Safford MM, Rosenson RS, Muntner P. Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Clin Lipidol 2020;14:720-9. [PMID: 32680814 DOI: 10.1016/j.jacl.2020.06.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Wang Q, Du L, Hong J, Chen Z, Liu H, Li S, Xiao X, Yan S. Molecular mechanism underlying the hypolipidemic effect of Shanmei Capsule based on network pharmacology and molecular docking. Technol Health Care 2021;29:239-56. [PMID: 33682762 DOI: 10.3233/THC-218023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res 2019;124:328-50. [PMID: 30653440 DOI: 10.1161/CIRCRESAHA.118.312782] [Cited by in Crossref: 143] [Cited by in F6Publishing: 76] [Article Influence: 47.7] [Reference Citation Analysis]
83 Smith I, Schmidt R, Halm EA, Mansi IA. Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses. Clin Drug Investig 2018;38:135-46. [PMID: 29081029 DOI: 10.1007/s40261-017-0589-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
84 de Denus S, Tardif JC, Dubé MP. CKing Precision in the Interpretation of Diagnostic Biomarkers. Circ Cardiovasc Genet 2017;10:e001874. [PMID: 28790156 DOI: 10.1161/CIRCGENETICS.117.001874] [Reference Citation Analysis]
85 Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, Benito-Vicente A, Martín C. Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci 2020;21:E4725. [PMID: 32630698 DOI: 10.3390/ijms21134725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
86 Mueller AM, Liakoni E, Schneider C, Burkard T, Jick SS, Krähenbühl S, Meier CR, Spoendlin J. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study. J Gen Intern Med 2021;36:2639-47. [PMID: 33751411 DOI: 10.1007/s11606-021-06651-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovasc Drugs Ther 2017;31:187-95. [PMID: 28466399 DOI: 10.1007/s10557-017-6727-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
88 Noel A, Genest J. Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. Can J Cardiol 2019;35:17-8. [PMID: 30595177 DOI: 10.1016/j.cjca.2018.11.022] [Reference Citation Analysis]
89 Katsiki N, Kolovou G, Perez-Martinez P, Mikhailidis DP. Dyslipidaemia in the elderly: to treat or not to treat? Expert Rev Clin Pharmacol 2018;11:259-78. [PMID: 29303009 DOI: 10.1080/17512433.2018.1425138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018;15:757-69. [PMID: 30375494 DOI: 10.1038/s41569-018-0098-5] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 30.0] [Reference Citation Analysis]
91 de Beer R, Outhoff K, Phulukdaree A, Soma P. Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa. Xenobiotica 2021;51:949-59. [PMID: 34154510 DOI: 10.1080/00498254.2021.1945165] [Reference Citation Analysis]
92 Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet 2018;57:769-79. [PMID: 29353350 DOI: 10.1007/s40262-017-0620-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
93 Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J 2017;38:2473-9. [PMID: 28077470 DOI: 10.1093/eurheartj/ehw628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
94 Volpe M, Volpe R, Gallo G, Presta V, Tocci G, Folco E, Peracino A, Tremoli E, Trimarco B; Italian Society of Cardiovascular Prevention (SIPREC) Writing Committee. 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. High Blood Press Cardiovasc Prev 2017;24:313-29. [PMID: 28523635 DOI: 10.1007/s40292-017-0211-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
95 Zhou Z, Albarqouni L, Breslin M, Curtis AJ, Nelson M. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017;7:e017587. [PMID: 28963307 DOI: 10.1136/bmjopen-2017-017587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
96 Mitchell D, Guertin JR, Lelorier J. Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. Mol Diagn Ther 2018;22:641-52. [DOI: 10.1007/s40291-018-0356-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract 2020;26:1196-224. [PMID: 33471721 DOI: 10.4158/CS-2020-0490] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 13.0] [Reference Citation Analysis]
98 Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics 2018;15:1006-17. [PMID: 30251222 DOI: 10.1007/s13311-018-0670-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
99 Inman LA, Rennie MJ, Watsford ML, Gibbs NJ, Green J, Spurrs RW. Reference values for the creatine kinase response to professional Australian football match-play. Journal of Science and Medicine in Sport 2018;21:852-7. [DOI: 10.1016/j.jsams.2017.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
100 Mefford MT, Tajeu GS, Tanner RM, Colantonio LD, Monda KL, Dent R, Farkouh ME, Rosenson RS, Safford MM, Muntner P. Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2018;122:768-74. [PMID: 30057227 DOI: 10.1016/j.amjcard.2018.05.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
101 Yee J, Kim H, Heo Y, Yoon HY, Song G, Gwak HS. Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis. J Pers Med 2021;11:677. [PMID: 34357144 DOI: 10.3390/jpm11070677] [Reference Citation Analysis]
102 Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Baek SH, Dalal J, Fong AYY, Li YH, O'Brien RC, Lim TSE, Koh SYN, Scherer DJ, Tada H, Kang V, Butters J, Nicholls SJ. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol 2020;16:837-51. [PMID: 32729743 DOI: 10.1080/17425255.2020.1802426] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Chien SC, Chen PS, Huang YH, Tang SC, Li YH, Yeh HI. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. J Formos Med Assoc 2019;118:1385-92. [PMID: 30584005 DOI: 10.1016/j.jfma.2018.11.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
104 Li W, Zhang Y, Tian Z, Zhu W, Liu J, Zhang Y, Yang X, Tian DC. Statin treatment for unruptured intracranial aneurysms study: a study protocol for a double-blind, placebo-controlled trial. Stroke Vasc Neurol 2020;5:410-5. [PMID: 32381630 DOI: 10.1136/svn-2020-000353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
105 Xiao M, Zhang L, Zhong Y, Xiao G. Sudden rhabdomyolysis in an elderly patient after single atorvastatin dose: The need for early and frequent creatine kinase monitoring in high-risk patients. SAGE Open Med Case Rep 2020;8:2050313X20919623. [PMID: 32728439 DOI: 10.1177/2050313X20919623] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Christopher-Stine L, Basharat P. Statin-associated immune-mediated myopathy: biology and clinical implications. Curr Opin Lipidol 2017;28:186-92. [PMID: 28207435 DOI: 10.1097/MOL.0000000000000399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
107 Tomlinson B, Lin CH, Chan P, Lam CW. Personalized medicine in lipid-modifying therapy. Per Med 2021;18:185-203. [PMID: 33565320 DOI: 10.2217/pme-2020-0110] [Reference Citation Analysis]
108 Sivashanmugarajah A, Fulcher J, Sullivan D, Elam M, Jenkins A, Keech A. Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle‐related side‐effects. Intern Med J 2019;49:1081-91. [DOI: 10.1111/imj.14429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
109 Rosenson RS. Trial designs for statin muscle intolerance. Curr Opin Lipidol 2017;28:488-94. [PMID: 28832369 DOI: 10.1097/MOL.0000000000000454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Clemens KK, Shariff SZ, McArthur E, Hegele RA. Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. Lipids Health Dis 2018;17:8. [PMID: 29310674 DOI: 10.1186/s12944-017-0649-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
111 Daliri EB, Oh DH, Lee BH. Bioactive Peptides. Foods 2017;6:E32. [PMID: 28445415 DOI: 10.3390/foods6050032] [Cited by in Crossref: 140] [Cited by in F6Publishing: 94] [Article Influence: 28.0] [Reference Citation Analysis]
112 du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacology & Therapeutics 2017;175:1-16. [DOI: 10.1016/j.pharmthera.2017.02.029] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
113 Pulipati VP, Davidson MH. How I treat statin-associated side effects in an outpatient setting. Future Cardiol 2021. [PMID: 33464124 DOI: 10.2217/fca-2020-0153] [Reference Citation Analysis]
114 Barry AR, Beach JE, Pearson GJ. Prevention and management of statin adverse effects: A practical approach for pharmacists. Can Pharm J (Ott) 2018;151:179-88. [PMID: 29796131 DOI: 10.1177/1715163518768534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
115 Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, Marín A, Labrador-Horrillo M, Juárez C, Grau-Junyent JM. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol 2018;14:215-24. [PMID: 29473763 DOI: 10.1080/1744666X.2018.1440206] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 11.8] [Reference Citation Analysis]
116 Nogueira AA, Strunz CM, Takada JY, Mansur AP. Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy. Biomark Med 2019;13:619-26. [PMID: 31157560 DOI: 10.2217/bmm-2018-0379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
117 Valanti EK, Chroni A, Sanoudou D. The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease. Curr Opin Lipidol 2019;30:326-41. [PMID: 31157629 DOI: 10.1097/MOL.0000000000000615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
118 Damiani I, Corsini A, Bellosta S. Potential statin drug interactions in elderly patients: a review. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1133-45. [DOI: 10.1080/17425255.2020.1822324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
119 Taylor BA. Does Coenzyme Q10 Supplementation Mitigate Statin-Associated Muscle Symptoms? Pharmacological and Methodological Considerations. Am J Cardiovasc Drugs 2018;18:75-82. [DOI: 10.1007/s40256-017-0251-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]